Trials / Not Yet Recruiting
Not Yet RecruitingNCT07472647
SYS6090 Combination Therapy in Advanced Lung Cancer
A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 596 (estimated)
- Sponsor
- Shanghai JMT-Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYS6090 + pemetrexed + platinum-based chemotherapy | In this group, participants will receive SYS6090 in combination with pemetrexed and platinum-based chemotherapy. |
| DRUG | SYS6090 + paclitaxel + platinum-based chemotherapy | In this group, participants will receive SYS6090 in combination with paclitaxel and platinum-based chemotherapy. |
| DRUG | SYS6090 + docetaxel | In this group, participants will receive SYS6090 in combination with docetaxel. |
| DRUG | SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy | In this group, participants will receive SYS6090 in combination with pemetrexed, bevacizumab, and platinum-based chemotherapy |
| DRUG | SYS6090 + SYS6010 | In this group, participants will receive SYS6090 and SYS6010. |
| DRUG | SYS6090 + etoposide + platinum-based chemotherapy | In this group, participants will receive SYS6090 in combination with etoposide and platinum-based chemotherapy. |
| DRUG | SYS6090 + chemotherapy or other anticancer therapy | In this group, participants will receive SYS6090 in combination with chemotherapy or other anticancer therapies. |
Timeline
- Start date
- 2026-02-28
- Primary completion
- 2029-02-28
- Completion
- 2030-02-28
- First posted
- 2026-03-16
- Last updated
- 2026-03-16
Source: ClinicalTrials.gov record NCT07472647. Inclusion in this directory is not an endorsement.